Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 0.45 |
| ▸ | MPEG1 | Q2M385 | 9/20 | 0.45 |
| ▸ | XIAP | P98170 | 2/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931939 | 0.91 | ALOX5 (0.43) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL2981062 | 0.73 | ALDH1A1 (0.39) | ALOX5MPEG1ALDH1A1MAPTTDP1 | |
| SCHEMBL7365320 | 0.71 | ALOX5 (0.65) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL11086905 | 0.69 | ALOX5 (0.49) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL1535483 | 0.69 | ALOX5 (0.49) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL11081517 | 0.69 | ALOX5 (0.49) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL11080211 | 0.69 | ALOX5 (0.49) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL4309680 | 0.69 | ALOX5 (0.49) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL28192948 | 0.69 | ALOX5 (0.49) | ALOX5MPEG1XIAPGPR84KDM4E | |
| SCHEMBL28642404 | 0.69 | ALDH1A1 (0.48) | ALOX5MPEG1XIAPGPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
| EP-1780201-A2 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R&D Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | CELLTECH R&D LIMITED | 2007-02-01 | — | — | US | disclosed |
| US-7122556-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-6878718-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20050038084-A1 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED | 2005-02-17 | — | — | US | disclosed |
| EP-1370531-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R & D Limited (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002068393-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, AGTR2 | ALOX5 2829/4885MPEG1 1930/4885XIAP 2719/4885 |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | ALOX5 2629/4885MPEG1 2164/4885XIAP 2189/4885 |
| US-20050038084-A1 | Phenylalanine enamide derivatives | PAH, ARRB1, ACVR2B | ALOX5 2340/4885MPEG1 2081/4885XIAP 2243/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | ALOX5 1759/4885MPEG1 2358/4885XIAP 1585/4885 |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | ALOX5 843/4885MPEG1 1827/4885XIAP 2925/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | ALOX5 2629/4885MPEG1 2164/4885XIAP 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.